Pneumococcal capsular polysaccharide-specific IgA triggers efficient neutrophil effector functions via FcalphaRI (CD89)
- PMID: 10979910
- DOI: 10.1086/315825
Pneumococcal capsular polysaccharide-specific IgA triggers efficient neutrophil effector functions via FcalphaRI (CD89)
Abstract
Specific anti-capsular polysaccharide IgG is believed to be important for protection against infection by Streptococcus pneumoniae. Significant IgA responses have been observed after vaccination with pneumococcal vaccines, but the role of this isotype in anti-pneumococcal host defense is unclear. Here, it is shown that purified serum IgA specific for pneumococcal capsular polysaccharides can initiate efficient cellular effector functions, such as phagocytosis, via interaction with the myeloid IgA receptor, FcalphaRI (CD89). The efficiency of FcalphaR-triggered granulocyte effector functions was comparable to that of FcgammaRIIa (CD32), as shown in experiments with bispecific antibodies. These results support a role for polysaccharide-specific IgA in antipneumococcal cellular effector function and suggest that FcalphaRI represents an important leukocyte receptor for immunity against S. pneumoniae.
Similar articles
-
The Fc receptor for IgA (FcalphaRI, CD89).Immunol Lett. 2004 Mar 29;92(1-2):23-31. doi: 10.1016/j.imlet.2003.11.018. Immunol Lett. 2004. PMID: 15081523 Review.
-
Immunoglobulin A-mediated protection against Bordetella pertussis infection.Infect Immun. 2001 Aug;69(8):4846-50. doi: 10.1128/IAI.69.8.4846-4850.2001. Infect Immun. 2001. PMID: 11447159 Free PMC article.
-
Antibody response to pneumolysin and to pneumococcal capsular polysaccharide in healthy individuals and Streptococcus pneumoniae infected patients.Vaccine. 2004 Mar 12;22(9-10):1157-61. doi: 10.1016/j.vaccine.2003.09.025. Vaccine. 2004. PMID: 15003643 Clinical Trial.
-
FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.Blood. 1997 Dec 1;90(11):4485-92. Blood. 1997. PMID: 9373259
-
Immunoglobulin A: magic bullet or Trojan horse?Eur J Clin Invest. 2017 Feb;47(2):184-192. doi: 10.1111/eci.12716. Epub 2017 Jan 19. Eur J Clin Invest. 2017. PMID: 28024097 Review.
Cited by
-
Quantification of IgM and IgA anti-pneumococcal capsular polysaccharides by a new ELISA assay: a valuable diagnostic and prognostic tool for common variable immunodeficiency.J Clin Immunol. 2013 May;33(4):838-46. doi: 10.1007/s10875-012-9856-z. Epub 2012 Dec 29. J Clin Immunol. 2013. PMID: 23274802
-
IgA: Structure, Function, and Developability.Antibodies (Basel). 2019 Dec 5;8(4):57. doi: 10.3390/antib8040057. Antibodies (Basel). 2019. PMID: 31817406 Free PMC article. Review.
-
Opening the OPK Assay Gatekeeper: Harnessing Multi-Modal Protection by Pneumococcal Vaccines.Pathogens. 2019 Oct 23;8(4):203. doi: 10.3390/pathogens8040203. Pathogens. 2019. PMID: 31652741 Free PMC article.
-
Polyfunctional antibodies: a path towards precision vaccines for vulnerable populations.Front Immunol. 2023 Jun 27;14:1183727. doi: 10.3389/fimmu.2023.1183727. eCollection 2023. Front Immunol. 2023. PMID: 37600816 Free PMC article. Review.
-
Mucosal and systemic immune responses induced by intranasal immunization of recombinant Bacillus subtilis expressing the P97R1, P46 antigens of Mycoplasma hyopneumoniae.Biosci Rep. 2019 Oct 30;39(10):BSR20191126. doi: 10.1042/BSR20191126. Biosci Rep. 2019. PMID: 31492763 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous